Dark

SVRA
Savara Inc.
stock NASDAQ

At Close

Jun 18, 2025 3:59:59 PM EDT

2.07USD+1.471%(+0.03)886,444

0.00Bid 0.00Ask 0.00Spread

Pre-market

Jun 17, 2025 8:54:30 AM EDT

2.18USD+6.863%(+0.14)0

After-hours

Jun 18, 2025 4:38:30 PM EDT

2.07USD0.000%(0.00)8,419

OverviewOptionsHistoricalExchangesShortsNews

Jan 4, 2022

08:05AM EST Savara to Present at the H.C. Wainwright BIOCONNECT Virtual Conference Business Wire

Dec 2, 2021

04:05PM EST Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire

Nov 22, 2021

11:47AM EST Savara Shares Move Higher; Co Reports In Form4 Filing Director Buys 200K Shares At Average Price Of $1.08/Share Benzinga

Nov 15, 2021

08:05AM EST Savara to Participate in Two Upcoming Investor Healthcare Conferences Business Wire

Nov 12, 2021

08:30AM EST Savara Q3 Loss/shr $0.07 Vs. Loss/shr $0.18 Prior Year RTTNews

08:27AM EST Savara Q3 Net Loss $10.5 Mln Or $0.07/shr Vs Net Loss $11.1 Mln Or $0.18/shr Prior Year RTTNews

08:15AM EST Savara Q3 EPS $(0.07) Up From $(0.18) YoY Benzinga

08:05AM EST Savara Reports Third Quarter 2021 Financial Results and Provides Business Update Business Wire

Nov 10, 2021

08:05AM EST Savara to Present at the Jefferies London Healthcare Conference Business Wire

Oct 7, 2021

04:05PM EDT Savara to Present at the Inaugural Piper Sandler Lung Day Business Wire

Sep 7, 2021

08:05AM EDT Savara to Participate in Two Upcoming Investor Healthcare Conferences Business Wire

Sep 3, 2021

08:05AM EDT Savara Announces New Employment Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire

Aug 12, 2021

04:28PM EDT Savara Q2 EPS $(0.07) Up From $(0.16) YoY Benzinga

04:06PM EDT Savara Reports Second Quarter 2021 Financial Results and Provides Business Update Business Wire

Jul 7, 2021

08:07AM EDT Savara On Jul. 6 Entered Sales Agreement With Evercore Pursuant To Which Co. May Offer And Sell From Time To Time Common Stock Of Up To $60M Benzinga

Jul 6, 2021

04:05PM EDT Savara Inc Files For Mixed Shelf Offering Of Up To $250M Benzinga

Jun 30, 2021

10:51AM EDT Savara Announces First Patient Dosed In Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis Trial RTTNews

10:47AM EDT Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial Business Wire

May 26, 2021

08:05AM EDT Savara to Present at the Jefferies Virtual Healthcare Conference Business Wire

May 17, 2021

08:05AM EDT Savara to Present at the Oppenheimer Rare & Orphan Disease Virtual Summit Business Wire

May 14, 2021

08:05AM EDT Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire

May 13, 2021

04:23PM EDT Savara Q1 EPS $(0.13) Up From $(0.27) YoY Benzinga

04:06PM EDT Savara Reports First Quarter 2021 Financial Results and Provides Business Update Business Wire

Mar 17, 2021

07:43AM EDT The Daily Biotech Pulse: Merck's Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity Spikes Benzinga

Mar 16, 2021

02:46PM EDT Mid-Afternoon Market Update: Crude Oil Down 1%; SunLink Health Systems Shares Spike Higher Benzinga

02:46PM EDT Mid-Day Market Update: Dow Falls 100 Points; Can-Fite BioPharma Shares Jump Benzinga

10:40AM EDT Thinking About Buying Stock In AstraZeneca, Apple, McDonald's, Savara Or Jabil? Benzinga

10:38AM EDT Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2021 Benzinga

08:17AM EDT The Daily Biotech Pulse: Fulgent Nabs CDC Contract, Enzo Rallies, Solid Biosciences Releases Gene Therapy Data, Moderna Begins Pediatric Vaccine Study Benzinga

06:21AM EDT Piper Sandler Initiates Coverage On Savara with Overweight Rating, Announces Price Target of $7 Benzinga

Mar 15, 2021

02:51PM EDT Savara CFO David Lowrance Reported Purchase of 13,793 @ Avg Price: $1.45/Share in Form 4 Filing Benzinga

02:50PM EDT Savara Inc: Lowrance David L (CHIEF FINANCIAL OFFICER) Buys 13,793 @ Avg Price: $1.45 (Form4) Benzinga

11:09AM EDT Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2021 Benzinga

09:36AM EDT Savara Reports Closing Of $130 Mln Public Offering Following Full Exercise Of Underwriters' Option RTTNews

09:32AM EDT Savara Announces Closing of $130 Million Public Offering Following Full Exercise of Underwriters' Option Business Wire

07:26AM EDT Oppenheimer Initiates Coverage On Savara with Outperform Rating, Announces Price Target of $4 Benzinga

Mar 11, 2021

09:10AM EST Savara Prices Public Offering Of 45.78 Mln Shares At $1.45 Per Share RTTNews

08:58AM EST Savara Prices 45,785,828 Share Common Stock Offering At $1.45/Share Benzinga

08:57AM EST Savara Announces Pricing of Public Offering of Common Stock Business Wire

08:19AM EST The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From Prothena Benzinga

Mar 10, 2021

04:50PM EST Savara Announces A Common Stock Offering; No Size Disclosed Benzinga

04:49PM EST Savara Announces Proposed Public Offering of Common Stock Business Wire

04:18PM EST Savara 8-K Shows Co. Entered Master Services Deal With Parexel To Provide Contract Services Related To Clinical Trials Conducted By Co., No Terms Disclosed Benzinga

Dec 15, 2020

09:54AM EST 10 Biggest Price Target Changes For Tuesday Benzinga

06:21AM EST HC Wainwright & Co. Maintains Buy on Savara, Lowers Price Target to $3 Benzinga

Dec 10, 2020

08:11AM EST Savara Announces Phase 3 AVAIL Trial Missed Primary Endpoint, Co. Stopping Further Development Of AeroVanc Benzinga

08:10AM EST Savara Provides Pipeline And Business Update; Co. Discontinues Development Of Apulmiq Program, Focuses Resources On Molgradex In aPAP, Reduces Operating Expenses 'to Align with Streamlined Development Programs' Benzinga

08:05AM EST Savara Provides Pipeline and Business Update Business Wire

Nov 24, 2020

04:15PM EST Savara Announces Participation in Fireside Chats at Two Upcoming Virtual Investor Healthcare Conferences Business Wire

Nov 11, 2020

04:05PM EST Savara to Present at the Jefferies Virtual London Healthcare Conference Business Wire

Nov 5, 2020

05:52PM EST Savara Q3 EPS $(0.18) Up From $(0.30) YoY, Sales $256.00K Benzinga

04:20PM EST Savara Reports Third Quarter 2020 Financial Results and Provides Business Update Business Wire

Sep 11, 2020

08:07AM EDT Savara Reports Chair, CEO, Rob Neville, Resigns; Names Matthew Pauls Chair, Interim CEO Benzinga

08:05AM EDT Savara Announces Senior Management Changes Business Wire

Sep 9, 2020

04:05PM EDT Savara to Present at the 22nd Annual H.C. Wainwright Annual Investment Conference Being Held Virtually Business Wire

Sep 8, 2020

08:05AM EDT Savara Announces New England Journal of Medicine (NEJM) Publication of IMPALA Study Results Business Wire

Sep 3, 2020

04:10PM EDT Savara To Discontinue Exploratory ENCORE Study Evaluating Molgradex For Treatment Of NTM Lung Infection In People Living With Cystic Fibrosis Benzinga

04:05PM EDT Savara to Discontinue Exploratory ENCORE Study Evaluating Molgradex for the Treatment of NTM Lung Infection in People Living With Cystic Fibrosis (CF) Business Wire

Aug 6, 2020

04:24PM EDT Savara Q2 EPS $(0.16) Beats $(0.24) Estimate Benzinga

04:02PM EDT Savara Reports Second Quarter 2020 Financial Results and Provides Business Update Business Wire

Aug 5, 2020

08:05AM EDT Savara to Present at the 40th Annual Canaccord Genuity Global Growth Conference to be Held Virtually Business Wire

Jul 30, 2020

08:05AM EDT Savara to Report Second Quarter 2020 Financial Results and Provide Business Update Business Wire

document.getElementById("flYlXb").onerror = function(){this.style.display='none';}; .dark-mode .xqjPGq{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .xqjPGq{ color: #333333; background-color: white; border: 2px solid #333333; }SVRASavara Inc.stock NASDAQ

SVRA
Savara Inc.
stock NASDAQ